ANTI-OVARIAN CANCER PROPERTIES OF RU-486

RU-486 的抗卵巢癌特性

• 批准号: 8167995
• 负责人: Carlos Marcelo Telleria
• 金额: $ 0.25万
• 依托单位: UNIVERSITY OF SOUTH DAKOTA
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-05-01 至 2011-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8167995
• 关键词: Clinical; Computer Retrieval of Information on Scientific Projects Database; Contraceptive Agents; Disease; Drug usage; Feasibility Studies; Funding; Goals; Grant; Growth; Growth Inhibitors; Human; Institution; Label; Laboratories; Malignant Neoplasms; Malignant neoplasm of ovary; Medical; Mifepristone; Mus; Pharmaceutical Preparations; Politics; Property; Publishing; RU-486; Research; Research Personnel; Resources; Source; Steroids; United States National Institutes of Health; Work; abortion; anticancer research; cancer cell; design; preclinical study; research study

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The laboratory of Dr. Carlos Telleria is studying the anti-ovarian cancer properties of the synthetic steroid mifepristone, also known as RU-486. The anti-cancer activity is totally unrelated to the contraceptive properties (of mifepristone). These studies are pre-clinical studies of off-label uses for this drug. The utility of this drug for other medical illnesses has been underexplored and jeopardized by anti-abortion politics. The overall goal of the research in the laboratory is to study the feasibility of utilizing this synthetic steroid, originally designed for contraceptive purposes, for the treatment of ovarian cancer. Experiments from Dr. Telleria's laboratory, which have been supported through SD BRIN pilot grants, have recently been published in the June 1, 2007 issue of Clinical Cancer Research. They reveal that mifepristone is a potent inhibitor of the growth of ovarian cancer, demonstrated utilizing human ovarian cancer cells maintained in culture and mice carrying ovarian cancer disease. The growth inhibition effect of mifepristone for ovarian cancer is not related to the antiprogesterone activity that claims its contraceptive properties. Seth Parsons worked with Dr. Telleria's lab with support of supplemental funds during the summer of 2009 and the lab received $1000 in addition.

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 卡洛斯·特莱里亚博士的实验室正在研究合成类固醇米非司酮(又称RU-486)的抗卵巢癌特性。抗癌活性与(米非司酮)的避孕特性完全无关。这些研究是对该药物非标签用途的临床前研究。这种药物对其他医学疾病的效用一直未得到充分开发，并受到反堕胎政治的威胁。实验室研究的总体目标是研究利用这种最初用于避孕目的的合成类固醇治疗卵巢癌的可行性。 Telleria博士实验室的实验得到了SD Brin试点基金的支持，最近发表在2007年6月1日的《临床癌症研究》上。他们揭示了米非司酮是一种有效的卵巢癌生长抑制剂，利用培养的人卵巢癌细胞和携带卵巢癌疾病的小鼠证明了这一点。米非司酮对卵巢癌的生长抑制作用与其声称具有避孕作用的抗孕酮活性无关。2009年夏天，塞思·帕森斯在补充资金的支持下与特莱里亚博士的实验室合作，实验室还获得了1000美元的额外资金。